A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

A Phase IIa/IIb, Randomised, Double Blind, Placebo-controlled, Parallel-group Dose-finding Study to Examine the Efficacy and Safety of BI 1839100 Administered Orally Over a 12-week Treatment Period in Patients With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis With Clinically Meaningful Cough

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06360094
• Other study ID #: 1490-0004
• Secondary ID: 2023-510249-79-0
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: July 27, 2024
• Est. completion date: August 6, 2025

Study information

• Verified date: April 2024
• Source: Boehringer Ingelheim
• Contact: Boehringer Ingelheim
• Phone: 1-800-243-0127
• Email: clintriage.rdg[@]boehringer-ingelheim.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF.

Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo looks like BI 1839100 but does not contain any medicine. Participants take the treatment for 3 months. After 1 month of treatment, participants who take the highest dose will have coughing measured to find out if the medicine works. If it does not work, the study may be stopped. Participants who have IPF are in the study for slightly longer than 4 months. During this time, they visit the study site 7 times. This study will also measure the effects of BI 1839100 on coughing and lung function in a smaller group of people with PPF.

During the study, coughing is measured over 24 hours about once per month using a portable device given to participants to use during the study. Participants fill in questionnaires about their coughing. Doctors also perform breathing tests that measure how well the lungs are working at the site visits. Researchers compare the results between participants who take BI 1839100 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 230
• Est. completion date: August 6, 2025
• Est. primary completion date: July 21, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

For Idiopathic Pulmonary Fibrosis (IPF) cohort:

• Minimum age: 40 years

• Diagnosis of IPF

• Chronic cough (>8 weeks prior to Visit 1) attributed to IPF and refractory to treatment for known causes (Principal Investigator (PI) assessment)

• Cough Severity visual analogue scale (VAS) =30 mm at Visit 1 and Visit 2B

• Forced vital capacity (FVC) =45% of predicted normal at Visit 1

• Diffusing capacity of the lungs for carbon monoxide (DLCO) >25% of predicted normal at Visit 1

• Patients may be either:

• On stable therapy with nintedanib or pirfenidone for =12 weeks prior to Visit 1 and are planning to stay on this background treatment for the whole trial duration. Combination of nintedanib plus pirfenidone will not be allowed

• Not on therapy with nintedanib or pirfenidone for =12 weeks prior to Visit 1 (either antifibrotic (AF)-treatment naïve or previously discontinued) and do not plan to start or re-start AF treatment during the trial

• Patients aged =40 years when signing the informed consent

For Progressive Pulmonary Fibrosis (PPF) cohort:

• Minimum age: 18 years

• Diagnosis of PPF

• Chronic cough (>8 weeks prior to Visit 1) attributed to PPF, refractory to treatment for known causes (PI assessment)

• Cough Severity VAS =30 mm at Visit 1 and Visit 2B

• FVC =45% of predicted normal at Visit 1

• DLCO =25% of predicted normal at Visit 1

• If receiving immunomodulatory therapy for interstitial lung disease (ILD), allowed medications include tacrolimus, mycophenolate mofetil, or azathioprine (stable dose for 12 weeks prior to Visit 1)

• Patients may be either:

• On a stable therapy with nintedanib for =12 weeks prior to Visit 1 and are planning to stay on this background treatment for the whole trial duration

• Not on a therapy with nintedanib for =12 weeks prior to Visit 1 (either AF-treatment naïve or previously discontinued) and do not plan to start or re-start AF treatment during the trial

• Patients aged >18 years when signing the informed consent

Further inclusion criteria apply.

Exclusion criteria for IPF and PPF cohorts:

• Acute exacerbation of IPF/PPF within 12 weeks prior to Visit 1

• Forced expiratory volume in 1 second (Forced expiratory volume in 1 second (FEV1))/FVC <0.7 at Visit 1

• Known reversible airflow obstruction/response to bronchodilators

• In the opinion of the Investigator, other clinically significant pulmonary abnormalities, including primary bronchitic and bronchiectatic disorder

• Upper or lower respiratory tract infection within 4 weeks prior to Visit 1

• Ongoing chronic pulmonary infection (e.g. mycobacterial or fungal disease)

• Current smokers (tobacco use within the 6 months prior to Visit 1)

• Initiation or change in supplemental oxygen requirement during 4 weeks prior to Visit 1 Further exclusion criteria apply.

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Intervention

Drug:
• BI 1839100
BI 1839100
• Placebo
Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IPF cohort - Phase IIa: Change from baseline in 24-h cough frequency (Cough count (CC)/h)		At baseline, at week 4
Primary	IPF cohort - Phase IIb: Change from baseline in 24-h cough frequency (CC/h)		At baseline, at week 12
Secondary	IPF cohort - Phase IIa: Absolute change from baseline in Cough Severity Numerical rating scale (NRS) score	NRS: a single-item patient reported outcome measure to assess cough severity on a 11-point numerical rating scale ranging from 0 (no cough) to 10 (worst possible cough) with a recall period of the past 7 days. Higher scores indicate higher severity of cough.	At baseline, at week 4
Secondary	IPF cohort - Phase IIa: Absolute change from baseline in Cough Severity Visual analogue scale (VAS) score (mm)	VAS: the cough severity VAS is scored according to the distance between no cough (0) and the mark set by the participant, with higher distance indicating higher severity of cough.	At baseline, at week 4
Secondary	IPF cohort - Phase IIb: Cough responder status, defined as a =30% reduction in 24-h cough frequency (CC/h)		At baseline, at week 12
Secondary	IPF cohort - Phase IIb: Absolute change from baseline in Forced vital capacity (FVC) (mL)		At baseline, at week 12
Secondary	IPF cohort - Phase IIb: Absolute change from baseline in Cough Severity NRS score		At baseline, at week 12
Secondary	IPF cohort - Phase IIb: Absolute change from baseline in Cough Severity VAS score (mm)		At baseline, at week 12
Secondary	IPF cohort - Phase IIb: Absolute change from baseline in Living with Pulmonary Fibrosis (L-PF) symptom cough domain score	L-PF: the L-PF symptom module domain and total scores as well as the L-PF impact module total score ranges from 0 to 100, with higher scores indicating a greater impairment.	At baseline, at week 12
Secondary	IPF cohort - Phase IIb: Absolute change from baseline in Leicester Cough Questionnaire (LCQ) physical domain score	LCQ: the total score ranges from 3 to 21. A higher score indicates better cough specific quality of life.	At baseline, at week 12

External Links

•   Related Info